Related Experiment Video
Updated: Feb 9, 2026

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
Published on: August 9, 2019
A revised road map for the commitment of human cord blood CD34-negative hematopoietic stem cells
Keisuke Sumide1, Yoshikazu Matsuoka1, Hiroshi Kawamura1,2
1Department of Stem Cell Biology and Regenerative Medicine, Graduate School of Medical Science, Kansai Medical University, Hirakata, 573-1010, Osaka, Japan.
Abstract:
We previously identified CD34-negative (CD34-) severe combined immunodeficiency (SCID)-repopulating cells as primitive hematopoietic stem cells (HSCs) in human cord blood. In this study, we develop a prospective ultra-high-resolution purification method by applying two positive markers, CD133 and GPI-80. Using this method, we succeed in purifying single long-term repopulating CD34- HSCs with self-renewing capability residing at the apex of the human HSC hierarchy from cord blood, as evidenced by a single-cell-initiated serial transplantation analysis. The gene expression profiles of individual CD34+ and CD34- HSCs and a global gene expression analysis demonstrate the unique molecular signature of CD34- HSCs. We find that the purified CD34- HSCs show a potent megakaryocyte/erythrocyte differentiation potential in vitro and in vivo. Megakaryocyte/erythrocyte progenitors may thus be generated directly via a bypass route from the CD34- HSCs. Based on these data, we propose a revised road map for the commitment of human CD34- HSCs in cord blood.
More Related Videos
Related Concept Videos
Multipotency of Hematopoietic Stem Cells
Regulation of Hematopoietic Stem Cells
Lineage Commitment
Embryonic Stem Cells
Design Example: Alignment of a Road Line Using GIS
Adult Stem Cells

